Novan, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NOVN research report →
Companywww.novan.com
Novan, Inc. , a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases.
- CEO
- Paula Brown Stafford
- IPO
- 2016
- Employees
- 90
- HQ
- Durham, CA, US
Price Chart
Valuation
- Market Cap
- $2.64M
- P/E
- -0.11
- P/S
- 0.11
- P/B
- 0.45
- EV/EBITDA
- 0.20
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 68.74%
- Op Margin
- -149.90%
- Net Margin
- -82.85%
- ROE
- -170.66%
- ROIC
- -50.11%
Growth & Income
- Revenue
- $23.61M · 736.61%
- Net Income
- $-19,561,000 · 32.17%
- EPS
- $-0.89 · 47.34%
- Op Income
- $-35,390,000
- FCF YoY
- -3.93%
Performance & Tape
- 52W High
- $3.33
- 52W Low
- $0.08
- 50D MA
- $0.75
- 200D MA
- $1.14
- Beta
- -0.04
- Avg Volume
- 1.04M
Get TickerSpark's AI analysis on NOVN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 27, 23 | SANDERS MACHELLE | sell | 11,553 |
| Jun 6, 23 | John A. Donofrio | other | 85,000 |
| Jun 6, 23 | GAY JOHN M. | other | 200,000 |
| Jun 7, 23 | GAY JOHN M. | other | 65,000 |
| Jun 6, 23 | GAY JOHN M. | other | 65,000 |
| Jun 7, 23 | GAY JOHN M. | other | 20,669 |
| Jun 7, 23 | GAY JOHN M. | other | 65,000 |
| Jun 6, 23 | Geer W Kent | other | 103,092 |
| Jun 7, 23 | Geer W Kent | other | 36,101 |
| Jun 7, 23 | Geer W Kent | other | 36,101 |
Our NOVN Coverage
We haven't published any research on NOVN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NOVN Report →